This drug was chosen as a positive control since ACE inhibitors are the first line of treatment in hypertension and cardiac failure (Kementerian Kesihatan Malaysia, 2019) and it also possesses antioxidant activity (Bartosz et al., 1997; Benzie and Tomlinson, 1998). The gene discussed is ACE; the disease is hypertensive disorder.